The outcomes for patients diagnosed with prostate cancer depend on more than just rates of cure or survival. A considerable burden is experienced by men who require treatment for prostate cancer, in many cases arising from complications of the procedures themselves.
Many men who undergo surgery or radiation therapy have worse urinary, bowel (respectively) and erectile function after treatment than they did before1, which can have a substantial negative effect on their mental health2.
Refinement of treatment approaches to prostate cancer have drastically improved survival over the past 20-30 years, but this has come with the cost of long-term morbidity for many men.
Some innovations in prostate cancer care during this time have had little, if any, effect on postoperative complications (including the use of robotics3).
With advanced medical imaging techniques, such as multiparametric MRI4, specific targeting of prostate cancer tumours has become possible.
Focal therapy, in which targeted ablation of only cancerous tissue is achieved (using, for example, high-intensity focused ultrasound, cryotherapy, or laser), offers the possibility of good outcomes in terms of metastasis- and cancer-free survival, and avoidance of treatment complications, in men with low or intermediate stage localised prostate cancer5.
In contrast to worsening urinary symptoms and erectile dysfunction after prostatectomy1, focal therapy appears to preserve these functions in men, for years after treatment5,6.
Critically, focal therapy looks to be as effective, for at least eight years, as prostatectomy, for treating prostate cancer7.
Unfortunately, there are currently no data available from randomised trials of focal therapy versus prostatectomy to guide practice; these will come soon, from at least three prospective clinical trials.
Until then, patients should be encouraged by the continuing advances in prostate cancer treatment, and the potential of good long-term treatment outcomes from the point of view of survival and quality of life.
